Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Company Overview

22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. Our primary mission in tobacco is to reduce the harm caused by smoking by bringing our proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets. Our primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Investor Contact Information


22nd Century Group, Inc.
500 Seneca Street, Suite 507
Buffalo, NY 14204
T: 716-270-1523
Contact Us

Investor Relations

Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
500 Seneca Street, Suite 507
Buffalo, NY 14204
T: 716-300-1221

Transfer Agent

Continental Stock and Transfer Company
1 State Street, 30th Floor
New York, NY 10004
T: 212-509-4000